肿瘤药学2016，Vol.6Issue(5)：338-342,5.DOI:10.3969/j.issn.2095-1264.2016.05.04
配体靶向纳米药物抗肿瘤的研究进展
The Research Progress of Ligand-targeted Particulate Nanomedicines against Tumor
黄晓宇 1贾晓燕 1李蕾 1夏秀梅 1鲁斌1
作者信息
- 1. 武汉科技大学附属孝感医院消化内科，湖北孝感，432100
- 折叠
摘要
Abstract
There are 13 kinds of ligand-targeted particulate nanomedicines (PNMs) which have stepped into clinical tri-als so far, including delivery forms based on liposomes, polymers, retrovirus vectors and bacteria-derived cells and so on. This review emphasized the research progress about 13 kinds of ligand-targeted PNMs. Main contents included:(1) the preliminary clinical trials of ligand-targeted PNMs;(2) the application of ligand-targeted PNMs in malignant tumor;(3) the role of ligands in PNMs;(4) the acting positions of ligand-targeted PNMs in target tissue are not subject to ligands. This advantage will help for location, and then improve their specificity. In the end, we talked about the prospect development of ligand-targeted PNMs.关键词
纳米治疗靶向配体/纳米载体/脂质体聚合物/纳米粒逆转录病毒载体Key words
Ligand-targeted/Nanoparticle therapy/Nano-carrier/Liposome polymer/Nanoparticle-retrovirus vector分类
医药卫生引用本文复制引用
黄晓宇,贾晓燕,李蕾,夏秀梅,鲁斌..配体靶向纳米药物抗肿瘤的研究进展[J].肿瘤药学,2016,6(5):338-342,5.
